Topics:
Clinical pharmacology
22/03/2004 00:00:00
Current versions available to download
Current translated versions available to download:
Authors
J. Lopez-Sendon FESC (Chairperson), K. Swedberg FESC, J. McMurray FESC, J. Tamargo FESC, A. P. Maggioni FESC, H. Dargie FESC, M. Tendera FESC, F. Waagstein FESC, J. Kjekshus FESC, P. Lechat FESC, C. Torp-Pedersen FESC
Endorsed by:
Table of contents: Full Text (ESC Clinical Practice Guidelines)
Pharmacology
- Definition
- Classification of b-blockers
- Pharmacokinetic properties: Lipophilic drugs, Hydrophilic drugs, Balanced clearance drugs
- Mechanism of action
- Adverse events: Cardiovascular, Metabolic, Pulmonary, Central effects, Sexual dysfunction
- Contraindications
- Drug interactions
- Dosing of b-blockers
Clinical efficacy and use
- Acute myocardial infarction (AMI)
- Secondary prevention after myocardial infarction
- Non-ST-segment elevation acute coronary syndromes
- Chronic, stable ischaemic heart disease
- Heart failure: Heart failure and preserved systolic function, Acute heart failure
- Arrhythmias: Sinus tachycardia, Supraventricular tachycardias, Tachycardias in WPW syndrome, Atrial flutter, Atrial fibrillation, Ventricular arrhythmias
- Prevention of sudden cardiac death: Acute myocardial infarction, Heart failure, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Mitral valve prolapse, Myocardial bridging, Long QT syndrome (LQTS), Catecholaminergic polymorphic ventricular tachycardia, SCD in the normal heart, Other situations
Hypertension, Aortic dissection, Hypertrophic cardiomyopathy, Prophylactic use in non-cardiac surgery, Vasovagal syncope, b-Blockers during pregnancy
Previous versions
A complete list of ESC Clinical Practice Guidelines (current and previous versions) endorsed by ESC National Society Members is available here